Latest news with #Baricitinib
Economic Times
5 days ago
- Business
- Economic Times
AI and machine learning: Driving a global tech revolution worth trillions
Artificial Intelligence (AI) and Machine Learning (ML) have transformed from a futuristic vision to the fundamental forces behind the world's major tech-empowered industrial revolution. From financial markets to other industries such as healthcare, retail, and manufacturing, AI and ML are no longer supplementary technologies. They are the engines powering innovation, productivity, and economic growth globally. Artificial intelligence is the most prominent commercial opportunity in the rapidly evolving world, with the potential to contribute $15.7 trillion to the global economy by 2030, as indicated by a recent report by PwC. As per the report published by Grand View Research, machine learning, a subset of AI, is anticipated to expand at a compound annual growth rate (CAGR) of over 36% between 2024 and 2030. Transforming global industries at unprecedented speed AI and ML are having an impact on many industries globally. These technologies are transforming business operations, making them more efficient and allowing data-driven decisions in various business domains. It is changing business models and generating unprecedented innovation globally. How? Healthcare AI-powered diagnostic equipment is leading to an earlier and more accurate diagnosis of diseases such as cancer and heart disease. It is assisting in early disease detection and increasing survival chances considerably. Predictive analytics assists hospitals in determining the patients at risk, lowering the rate of readmission by more than 25%. Artificial intelligence is changing the delivery of healthcare services in developed and developing countries, including drug invention and remote discovery. For example, it was discovered using BenevolentAI's AI platform, which analysed vast biomedical datasets to predict how existing drugs could interact with Covid-19 pathways. The AI suggested Baricitinib as a potential medicine within days, something that traditionally could have taken months, helping accelerate clinical trials and eventual emergency approvals. Finance Fraud detection tools empowered with artificial intelligence monitor billions of transactions in real time, and automated trading algorithms make transactions in a matter of seconds. JPMorgan Chase report points out that over $150 million is saved annually through AI-enabled systems. Global consumer financial services are also being secured, liberalised, and personalised through AI-driven banking services. Retail and e-commerce AI-powered predictive analytics can forecast customer purchasing habits with a predicted 90 percent accuracy. It enables retailers to predict demand and customise inventory to ensure the most sales are made, and reduce wastage of stock. These technologies allow dynamic pricing, filtering product recommendations according to the tastes and preferences of customers, acceleration of order placements, easier shopping experiences, and increased satisfaction among customers in both online and offline stores. Manufacturing AI-enabled predictive maintenance systems help factories by predicting breakdowns of equipment before they actually occur, up to a 60% improvement in equipment lifetime alongwith reduction in downtime. This not only saves millions of operational costs, but also improves worker safety. AI-empowered robotics is also becoming involved in complicated and risky operations, increasing productivity and product quality globally. The global AI market size, valued at $196.6 billion in 2024, is projected to surpass $1.8 trillion by 2030. North America currently leads in adoption, but Asia-Pacific is the fastest-growing region, with investments in AI startups increasing year-on-year. Agriculture AI is also poised to play a pivotal role in addressing global challenges. Climate scientists are leveraging AI to model weather patterns and optimise renewable energy grids, potentially reducing carbon emissions by up to 10% annually (Source: In developing economies, AI is enabling leapfrog growth. Empowering people and boosting economies through the AI & ML revolution While automation raises concerns of job loss, the statistics showcase a clearer picture. World Economic Forum estimations show that by the end of 2025, AI will create 97 million new jobs in fields such as AI engineering, data science, as compared to the 85 million jobs already existing in the market (Source: Artificial intelligence development companies are spending heavily on employee upskilling in response to this change. Google AI training already has more than 3 million learners worldwide, and IBM has committed to skilling up to 30 million people by 2030 globally. " Every technological revolution disrupts the job market, but it also creates new opportunities that didn't exist before, " said Naveen Khanna, CEO of Octal IT Solution, which is a leading mobile app development company. " The AI era is no different, and the winners will be those who adapt fastest. " Navigating the ethics and regulatory guidelines of AI innovation With the faster AI adoption rate, ethical and regulatory systems are taking centre stage. The AI Act of the European Union is projected to become fully operative by 2026. It will establish the first complete regulatory framework for the worldwide use of AI. In the meantime, major economies and nations, are implementing specific policies towards AI and machine learning solutions to make it safer and accountable to innovation. A PwC survey revealed that 94% of organizations accepts that they have implemented or planning to implement AI in their business operations as AI ethics will be critical to building trust with stakeholders. Issues related to biased algorithms of AI, data-related privacy, and transparency still exist, yet widely used responsible AI principles are being adopted by companies. Gartner reports that by 2027, organizations will implement small, task-specific AI models, with usage volume at least 3 times more than those of general-purpose large language models (LLMs). Driving the future: AI and ML as the ultimate game changer The AI and ML will become fundamental to business competitiveness in this decade, as the internet did in earlier periods. Early adopters are already reaping exponential gains, while latecomers risk being left behind. Octal IT Solutions is also committed to providing AI-powered solutions that have delivered up to 45% operational efficiency improvements and 30% cost reductions for enterprises. " AI is no longer about replacing humans; it's about augmenting their capabilities ," said Arun Goyal, MD, Octal IT Solution, one of the leading voices in AI innovation. "This shift is empowering businesses to make better decisions, streamline operations, and open entirely new markets that didn't exist a decade ago." AI and ML are no longer optional; they are the driving forces shaping the next era of global innovation and economic growth. Businesses, industries, and nations that embrace this transformation today will define the competitive landscape of tomorrow. Disclaimer - The above content is non-editorial, and TIL hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content.
Globe and Mail
15-04-2025
- Health
- Globe and Mail
Rheumatoid Arthritis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Revenue, Statistics, Therapies, and Companies by DelveInsight
"Rheumatoid Arthritis Treatment Market" Rheumatoid Arthritis Companies are Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others. (Albany, USA) DelveInsight's "Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2034" report delivers an in-depth understanding of rheumatoid arthritis, historical and forecasted epidemiology as well as the Rheumatoid arthritis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The Rheumatoid Arthritis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Rheumatoid Arthritis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Rheumatoid Arthritis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Rheumatoid Arthritis market. Key Takeaways from the Rheumatoid Arthritis Market Report According to DelveInsight, Rheumatoid Arthritis Market Size in the 7MM was estimated to be around USD 29,000 million in 2023, which is expected to grow during the forecast period (2024–2034). Among the 7MM, the US accounted for the highest prevalent cases of rheumatoid arthritis in 2023, with around 1,430,000 cases were diagnosed with rheumatoid arthritis. Moreover, these cases are expected to increase during the forecast period. Amongst EU4 and the UK, the diagnosed prevalent cases of rheumatoid arthritis were highest in Germany, while the lowest number of cases was in France in 2023. In the US, the total age-specific prevalent cases of rheumatoid arthritis were highest in the age group for 55-64 years in 2023. The leading Rheumatoid Arthritis Companies such as Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others. Promising Rheumatoid Arthritis Therapies such as Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others. In February 2025, Inmedix® introduced its CloudHRV™ System to U.S. rheumatologists during the Rheumatology Winter Clinical Symposium held in Wailea, Maui. Cleared for commercialization by the U.S. FDA on January 17, 2025, the CloudHRV System is a heart rate variability (HRV) diagnostic tool intended for clinical use at the discretion of healthcare providers. In February 2025, Zydus Lifesciences received final approval from the U.S. FDA to manufacture Ibuprofen and Famotidine tablets (800 mg/26.6 mg), marketed under the brand name Duexis. This combination therapy is prescribed for the relief of rheumatoid arthritis and osteoarthritis symptoms while also reducing the risk of upper gastrointestinal ulcers associated with long-term ibuprofen use. In January 2025, Celltrion, a prominent South Korean biopharmaceutical firm, announced U.S. FDA approval for its biosimilar Avtozma. Developed as a biosimilar to Actemra, Avtozma is available in both intravenous and subcutaneous forms and is indicated for autoimmune conditions such as rheumatoid arthritis, giant cell arteritis, and COVID-19. Additionally, in January 2025, Rise Therapeutics reported that the FDA accepted its Investigational New Drug (IND) application for a Phase 1 oncology trial of R-5780. The company continues to develop treatments targeting ulcerative colitis, rheumatoid arthritis, and type 1 diabetes. In September 2024, Celltrion announced FDA approval for a Phase 3 clinical study of Zymfentra (CT-P13 SC, infliximab), its subcutaneous Remicade biosimilar, for rheumatoid arthritis treatment. June 2024:- AbbVie- A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and Who Had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH). Rheumatoid Arthritis Overview Rheumatoid Arthritis is a chronic autoimmune disorder that primarily affects the joints, leading to inflammation, pain, and potential joint deformity. Rheumatoid Arthritis occurs when the immune system mistakenly attacks the synovium—the lining of the membranes that surround the joints. Rheumatoid Arthritis symptoms typically include joint stiffness, swelling, fatigue, and reduced range of motion, often affecting the wrists, hands, and knees symmetrically. Rheumatoid Arthritis diagnosis involves a combination of physical examinations, blood tests for inflammatory markers, and imaging techniques such as X-rays or MRIs to assess joint damage. Rheumatoid Arthritis progression can vary widely, with some individuals experiencing mild symptoms and others facing significant disability if left untreated Rheumatoid Arthritis treatment focuses on controlling inflammation and slowing disease progression through medications such as Disease-Modifying Anti-Rheumatic Drugs (DMARDs), biologics, and corticosteroids. Rheumatoid Arthritis management may also include lifestyle changes, physical therapy, and in severe cases, surgical intervention. Rheumatoid Arthritis research continues to advance, aiming for more targeted therapies and earlier diagnosis. Rheumatoid Arthritis awareness is essential for early detection and intervention, which can significantly improve long-term outcomes. Rheumatoid Arthritis patients benefit from a multidisciplinary approach involving rheumatologists, physical therapists, and support groups to enhance quality of life and manage daily challenges. Learn more about Rheumatoid Arthritis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Rheumatoid Arthritis Treatment Market Rheumatoid Arthritis Epidemiology The Rheumatoid Arthritis epidemiology section provides insights into the historical and current Rheumatoid Arthritis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Rheumatoid Arthritis market report also provides the diagnosed patient pool, trends, and assumptions. Rheumatoid Arthritis Epidemiology Segmentation: Download the report to understand which factors are driving Rheumatoid Arthritis Epidemiology trends @ Rheumatoid Arthritis Prevalence Rheumatoid Arthritis Marketed Drugs • OLUMIANT (barticinib): Eli Lilly and Company/Incyte Corporation OLUMIANT is an immunosuppressant that is indicated for use in inflammatory and autoimmune diseases, or in other terms, it is defined as a Janus kinase (JAK) inhibitor used to treat adults with moderate to severe RA who have not responded well enough to or could not tolerate at least one medicine called a tumor necrosis factor (TNF) antagonist. This novel agent achieved its approval on the basis of well-conducted late-stage clinical trials in countries like the US, Europe, and Japan. OLUMIANT is approved with a Boxed Warning for the risk of serious infections, malignancies, and thrombosis. Currently, OLUMIANT is conducting a Phase II trial (NCT04870203) in combination with adalimumab in rheumatoid arthritis • RINVOQ (upadacitinib): AbbVie RINVOQ- an AbbVie product is a prescription medicine used to treat adults with moderate to severe RA in whom methotrexate did not work well or could not be tolerated. In August 2019, AbbVie announced that the US FDA has approved RINVOQ for the treatment of adults with moderately to severely active RA who have had an inadequate response or intolerance to methotrexate. Rheumatoid Arthritis Emerging Drugs • Rabeximod (Rob 803): Cyxone Rabeximod is an orally available drug with a unique mechanism of action that selectively targets the inflammatory macrophage, a type of white blood cell that is the central orchestrator of the inflammatory process that causes tissue destruction and clinical symptoms in rheumatoid arthritis. Rabeximod has been extensively studied in Phase I and Phase II clinical trials. Safety studies reveal a favorable safety profile compared to anti-rheumatoid arthritis drugs such as anti-TNFα monoclonal antibodies and oral JAK inhibitors. In June 2022, Cyxone received a response from a Type B pre-IND meeting with the US FDA. The response from the FDA facilitates for Cyxone to continue planning the Phase IIb study with Rabeximod in rheumatoid arthritis. • Imvotamab: IGM Biosciences Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. It has 10 binding units for CD20, and it may successfully bind to CD20 expressing B cells with more power (avidity) compared to an IgG bispecific antibody with only one or two binding units for CD20. The company is currently evaluating Imvotamab in Phase-Ib trial for severe rheumatoid arthritis and mostly autoimmune diseases mediated by B-cells. Additionally, in vitro studies show that Imvotamab is significantly more effective than rituximab in depleting low CD20 expressing cells. Rheumatoid Arthritis Market Outlook Rheumatoid Arthritis aims to control pain and inflammation and, ultimately, the goal is remission or at least low disease activity. The FDA that can slow the course of the disease and improve the quality of life has approved scarcely any drugs. Therefore, the management of rheumatoid arthritis remains supportive and symptom-based. In recent years, research on new treatment strategies has increased, taking heed of monoclonal antibodies, small molecules, and others. There are limited approved drugs that slow disease progression by prolonging autonomy and increasing survival rates. Moreover, approved by the US FDA to treat rheumatoid arthritis, including OLUMIANT, RINVOQ, and ORENCIA. Rheumatoid Arthritis Drug Market The pipeline holds multiple promising therapies in various stages of development, most of which are vaccines. Therapies like Rabeximod (Cyxon), Imvotamab (IGM Biosciences), and others are the drugs and Monoclonal antibodies currently in Phase II and Ib trials focusing on Macrophage inhibition and CD cells depletion, and more may follow in the future. The current pipeline does not hold great potential as most of the products are currently in initial and mid stage trials and most of the drugs failed in their last stage trials as the studies did not meet primary and secondary efficacy endpoints in rheumatoid arthritis treatment. However, Rabeximod by Cyxone is a new drug candidate and unique among marketed drugs as well as drugs in development as it selectively targets rheumatoid arthritis via the NFkB pathway of inflammatory macrophages, the central orchestrators of the inflammatory process responsible for tissue destruction and clinical symptoms in rheumatoid arthritis. Scope of the Rheumatoid Arthritis Market Report Coverage- 7MM Rheumatoid Arthritis Companies- Major pharmaceutical and biotechnology companies such as Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Sanofi (EPA: SAN), Eli Lilly and Company (NYSE: LLY), UCB BIOSCIENCES GmbH (part of UCB S.A., EBR: UCB), AbbVie Inc. (NYSE: ABBV), Pfizer Inc. (NYSE: PFE), Changchun GeneScience Pharma (SHE: 000661), Novartis (SWX: NOVN), Istituto Giannina Gaslini, and others. Rheumatoid Arthritis Therapies- Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others. Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis Market Drivers and Barriers Rheumatoid Arthritis Market Access and Reimbursement, Unmet Needs and Future Perspectives Discover more about Rheumatoid Arthritis Drugs in development @ Rheumatoid Arthritis Clinical Trials Assessment and Pipeline Analysis Table of Content 1 Key Insights 2 Report Introduction 3 Executive Summary 4 Key Events 5 Epidemiology and Market Forecast Flow Methodology 6 Rheumatoid Arthritis Market Overview at a Glance 7 Disease Background and Overview 8 Treatment and Management of Rheumatoid Arthritis 9 Guidelines for Management of Rheumatoid Arthritis with Synthetic and Biological Disease-modifying Antirheumatic Drugs (European Alliance of Associations for Rheumatology) 10 Treatment Guidelines for RA (National Institute for Health and Care Excellence) 11 Guidelines for Management of RA (American College of Rheumatology) 12 Clinical Practice Guidelines for RA (Italian Society for Rheumatology) 13 Guidelines for the use of methotrexate in patients with Rheumatoid Arthritis (Japan College of Rheumatology (JCR)) 14 Treatment Algorithm 15 Epidemiology and Patient Population of 7MM 16 Patient Journey 17 Key Endpoints in Rheumatoid Arthritis Clinical Trials 18 Marketed Drugs 19 Emerging Drugs 20 Rheumatoid arthritis: 7MM Market Analysis 21 Unmet Needs 22 SWOT Analysis 23 Market Access and Reimbursement of Rheumatoid Arthritis Therapies 24 KOL Views 25 Appendix 26 DelveInsight Capabilities 27 Disclaimer 28 About DelveInsight About DelveInsight DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
